Pharmacovigilance and Adverse Drug Reactions

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the study, detection, monitoring, and reporting of adverse drug reactions (ADRs) through pharmacovigilance. It covers various aspects such as signal detection, drug safety surveillance, data mining techniques, patient reporting, regulatory actions, causality assessment, and the impact of ADRs on hospital admissions.

138

Works

IDs:OpenAlex

How has Pharmacovigilance and Adverse Drug Reactions's publication output changed over time?

ScholarIQpublication output · 2004–2022

Output grew0% over the shown period — from 1 works in 2004 to 1 in 2022.

2004201120122014201520162017201820192022

What are the most-cited papers on Pharmacovigilance and Adverse Drug Reactions?

ScholarIQmost cited works

The Danish National Prescription Registry

Helle Wallach‐Kildemoes, Henrik Toft Sørensen, Jesper Hallas

S163542868. 20112,483 CitationsOPEN ACCESS

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

Eugène van Puijenbroek, Andrew Bate, Hubert G.M. Leufkens, Marie Lindquist, Roland Orre, Toine C. G. Egberts

S140231191. 20021,340 Citations

The reporting odds ratio and its advantages over the proportional reporting ratio

Kenneth J. Rothman, Stephan Lanes, Susan T. Sacks

S140231191. 20041,091 Citations

Adverse drug events in hospitalized patients

Patricia M. L. A. van den Bemt, Toine C. G. Egberts, A.W. Lenderink, J.M. Verzijl, Katherine Simons, W.S.C.J.M. van der Pol, Hubert G.M. Leufkens

S31780008. 1999466 Citations

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Léa Hoisnard, Bénédicte Lebrun‐Vignes, Sébastien Maury, Matthieu Mahévas, Khalil El Karoui, Lydia Roy, Anissa Zarour, Marc Michel, José L. Cohen, Aurélien Amiot, Pascal Claudepierre, P. Wolkenstein, Philippe Grimbert, É. Sbidian

Scientific Reports. 2022182 CitationsOPEN ACCESS